TY - JOUR
T1 - Parkinson's disease biomarkers
T2 - Perspective from the NINDS Parkinson's Disease Biomarkers Program
AU - Gwinn, Katrina
AU - David, Karen K.
AU - Swanson-Fischer, Christine
AU - Albin, Roger
AU - Hillaire-Clarke, Coryse St
AU - Sieber, Beth Anne
AU - Lungu, Codrin
AU - Bowman, F. Dubois
AU - Alcalay, Roy N.
AU - Babcock, Debra
AU - Dawson, Ted M.
AU - Dewey, Richard B.
AU - Foroud, Tatiana
AU - German, Dwight
AU - Huang, Xuemei
AU - Petyuk, Vlad
AU - Potashkin, Judith A.
AU - Saunders-Pullman, Rachel
AU - Sutherland, Margaret
AU - Walt, David R.
AU - West, Andrew B.
AU - Zhang, Jing
AU - Chen-Plotkin, Alice
AU - Scherzer, Clemens R.
AU - Vaillancourt, David E.
AU - Rosenthal, Liana S.
N1 - Publisher Copyright:
© 2017 Future Medicine Ltd.
PY - 2017/6
Y1 - 2017/6
N2 - Biomarkers for Parkinson's disease (PD) diagnosis, prognostication and clinical trial cohort selection are an urgent need. While many promising markers have been discovered through the National Institute of Neurological Disorders and Stroke Parkinson's Disease Biomarker Program (PDBP) and other mechanisms, no single PD marker or set of markers are ready for clinical use. Here we discuss the current state of biomarker discovery for platforms relevant to PDBP. We discuss the role of the PDBP in PD biomarker identification and present guidelines to facilitate their development. These guidelines include: harmonizing procedures for biofluid acquisition and clinical assessments, replication of the most promising biomarkers, support and encouragement of publications that report negative findings, longitudinal follow-up of current cohorts including the PDBP, testing of wearable technologies to capture readouts between study visits and development of recently diagnosed (de novo) cohorts to foster identification of the earliest markers of disease onset.
AB - Biomarkers for Parkinson's disease (PD) diagnosis, prognostication and clinical trial cohort selection are an urgent need. While many promising markers have been discovered through the National Institute of Neurological Disorders and Stroke Parkinson's Disease Biomarker Program (PDBP) and other mechanisms, no single PD marker or set of markers are ready for clinical use. Here we discuss the current state of biomarker discovery for platforms relevant to PDBP. We discuss the role of the PDBP in PD biomarker identification and present guidelines to facilitate their development. These guidelines include: harmonizing procedures for biofluid acquisition and clinical assessments, replication of the most promising biomarkers, support and encouragement of publications that report negative findings, longitudinal follow-up of current cohorts including the PDBP, testing of wearable technologies to capture readouts between study visits and development of recently diagnosed (de novo) cohorts to foster identification of the earliest markers of disease onset.
UR - http://www.scopus.com/inward/record.url?scp=85021672747&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021672747&partnerID=8YFLogxK
U2 - 10.2217/bmm-2016-0370
DO - 10.2217/bmm-2016-0370
M3 - Review article
C2 - 28644039
AN - SCOPUS:85021672747
SN - 1752-0363
VL - 11
SP - 451
EP - 473
JO - Biomarkers in Medicine
JF - Biomarkers in Medicine
IS - 6
ER -